A Bamias
National and Kapodistrian University of Athens
H-index: 71
Europe-Greece
Top articles of A Bamias
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Intravesical administration of Durvalumab to patients with high risk non muscle invasive bladder cancer who experience BCG failure. Final results from a phase II study by the … | European Urology | C Fragkoulis E Fragkiadis M Sakellakis A Pinitas K Tzannis | 2023 |
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial | Annals of Oncology | AO Siefker-Radtke N Matsubara SH Park RA Huddart EF Burgess | 2024/1/1 |
Chemotherapy response score as a predictor of survival in ovarian cancer patients | European Journal of Obstetrics & Gynecology and Reproductive Biology | Ioannis Rodolakis Michalis Liontos Vasilios Pergialiotis Dimitrios Haidopoulos Maria Kaparelou | 2024/5/1 |
Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer | Cell Reports Medicine | Matthew D Galsky Xiangnan Guan Deepali Rishipathak Aaron S Rapaport Hesham M Shehata | 2024/2/20 |
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised … | The Lancet Oncology | Aristotelis Bamias Ian D Davis Matthew D Galsky José Á Arranz Eiji Kikuchi | 2024/1/1 |
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study | Clinical Genitourinary Cancer | Fernando Sabino Marques Monteiro Ondřej Fiala Francesco Massari Zin W Myint Jindrich Kopecky | 2024/4/1 |
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis … | The Lancet Oncology | Enrique Grande José Á Arranz Maria De Santis Aristotelis Bamias Eiji Kikuchi | 2024/1/1 |
Real-world outcome of patients with advanced renal cell carcinoma and intermediate-or poor-risk international metastatic renal cell carcinoma database consortium criteria … | European Urology Oncology | Matteo Santoni Sebastiano Buti Zin W Myint Marco Maruzzo Roberto Iacovelli | 2024/2/1 |
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) | Matteo Santoni Giandomenico Roviello Enrique Grande Ugo Giorgi Ondrej Fiala | 2024/3/21 | |
Pembrolizumab plus enfortumab vedotin in urothelial cancer | Matteo Santoni Hideki Takeshita Francesco Massari Aristotelis Bamias Linda Cerbone | 2024/1/24 | |
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study | Cancer Immunology, Immunotherapy | Francesco Massari Matteo Santoni Hideki Takeshita Yohei Okada Jose Carlos Tapia | 2024/6 |
Comprehensive 3DCRT Hypofractionated Radiotherapy Schedule for Localized Prostate Adenocarcinoma in the Era of IMRT: Dosimetric and Endoscopic Analysis | Cancers | Andromachi Kougioumtzopoulou Nick Syrigos Anna Zygogianni Ioannis Georgakopoulos Kalliopi Platoni | 2024/3/18 |
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study | Journal of Clinical Oncology | Robert J Motzer Camillo Porta Masatoshi Eto Thomas Powles Viktor Grünwald | 2024/1 |
PD34-11 NIVOLUMAB PLUS GEMCITABINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA: RESULTS … | The Journal of Urology | Guru Sonpavde Michiel S van der Heijden Thomas Powles Andrea Necchi Mauricio Burotto | 2024/5 |
Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma | New England Journal of Medicine | Michiel S van der Heijden Guru Sonpavde Thomas Powles Andrea Necchi Mauricio Burotto | 2023/11/9 |
Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract … | Cora N Sternberg Yohann Loriot Ernest Choy Daniel Castellano Fernando Lopez-Rios Moreno | 2023/6/1 | |
Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma | European Urology | Petros Grivas Evgeny Kopyltsov Po-Jung Su Francis X Parnis Se Hoon Park | 2023/4/1 |
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study | Cancer Immunology, Immunotherapy | Matteo Santoni Zin W Myint Thomas Büttner Hideki Takeshita Yohei Okada | 2023/9 |
Atezolizumab (atezo)+ platinum/gemcitabine (plt/gem) vs placebo+ plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final … | Matt D Galsky Jose Angel Arranz Arija Maria De Santis Ian D Davis Aristotelis Bamias | 2023/2/20 | |
2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with … | Annals of Oncology | S Gupta O Alhalabi A Bamias J Bellmunt DE Castellano Gauna | 2023/10/1 |
